Biocon Gains EMA Nod for Malaysia Insulin Line; European Supplies from Q2FY27

's Malaysian subsidiary has secured EMA approval for its new insulin glargine fill-finish line, with supplies to Europe projected to commence in the second quarter of financial year 2027. This approval strengthens Biocon's position as a major global biosimilar supplier following its acquisition of Viatris' biosimilars business. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.